The company said net revenues for Q2 2025 (3 months) were $2,761 million, up 15.2% from $2,397 million a year earlier. It said organic revenue growth accounted for 5.2% of that increase.

1. 01

   The company said net revenues for Q2 2025 (3 months) were $2,761 million, up 15.2% from $2,397 million a year earlier. It said organic revenue growth accounted for 5.2% of that increase.

2. 02

   Quest Diagnostics said reported diluted earnings per share for Q2 2025 were $2.47, up 21.7%, and adjusted diluted earnings per share were $2.62, up 11.5%. It said adjusted operating income for the same quarter was $466 million.

3. 03

   The company said net cash provided by operations for the first 6 months of 2025 was $858 million, up 67.1% from $514 million a year earlier. It said capital expenditures for the same period were $225 million.

4. 04

   The company set its full-year 2025 net revenue outlook at $10.80 billion to $10.92 billion (prior outlook $10.70 billion to $10.85 billion) and its adjusted diluted EPS outlook at $9.63 to $9.83 (prior $9.55 to $9.80).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.